Longitudinal measurement of airway inflammation relates to a higher risk of exacerbation in COPD

Bernardino Alcazar Navarrete, Francisca Castellano-Miñán, Oliverio Ruiz Rodriguez, Pedro J Romero Palacios
  • September 2017, European Respiratory Society (ERS)
  • DOI: 10.1183/1393003.congress-2017.pa399

FeNO is a valuable tool for managing COPD

What is it about?

Exhaled Nitric Oxide measurement (FeNO) is a simple test that has been used for many years in asthma management. It´s not clear yet if FeNO could be of value in COPD. This study is aimed to evaluate if FeNO could detect COPD patients at a higher risk of exacerbations

Why is it important?

For the first time, we demonstrate that COPD patients with persistent high FeNO levels are at a higher risk of moderate and severe COPD exacerbations.

Perspectives

Bernardino Alcazar Navarrete

FeNO could be used to target therapy (ICS) in COPD patients when aiming to prevent exacerbations

Read Publication

http://dx.doi.org/10.1183/1393003.congress-2017.pa399

The following have contributed to this page: Bernardino Alcazar Navarrete

In partnership with: